CONCORDBIO

Concord Biotech Balance Sheet

₹1,358.80-0.73%
Market cap
₹14,215 crore
P/E
52.0
P/B
7.05
ROE
13.6%
Dividend yield
0.56%

As of Mar 2022, Concord Biotech had total assets of ₹13,700 crore and borrowings of ₹1,200 crore, against shareholders' equity of ₹9,000 crore — a debt-to-equity ratio of 0.13. Borrowings rose 3,703.49% from Mar 2023.

Concord Biotech balance sheet

As at each financial year end, newest first. H1 = half-year.

Concord Biotech balance sheet (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital50010.4610.4610.4610.46
Reserves8,5001,1681,4051,6911,896
Borrowings1,20031.559.742.972.32
Other liabilities3,500192164219217
Total liabilities13,7001,5141,7012,0342,235
Fixed assets6,500773794852876
Capital work in progress400100100100100
Investments2,500303340407447
Other assets4,300454510610670
Total assets13,7001,5141,7012,0342,235

Balance sheet ratios

Debt to equity
0.13

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Concord Biotech balance sheet — frequently asked questions

What is the total debt of Concord Biotech?

Concord Biotech reported borrowings of ₹1,200 crore as of Mar 2022, compared with ₹31.55 crore as of Mar 2023.

What is Concord Biotech's debt-to-equity ratio?

Based on the Mar 2022 balance sheet, Concord Biotech's debt-to-equity ratio is 0.13 — borrowings of ₹1,200 crore against equity capital and reserves of ₹9,000 crore.

What are Concord Biotech's total assets?

Concord Biotech's total assets were ₹13,700 crore as of Mar 2022, including fixed assets of ₹6,500 crore and investments of ₹2,500 crore.

Same Data For Peers

Trade Concord Biotech With ATS

Track CONCORDBIO live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.